Cencora, Inc.

Cencora, Inc.

CORNYSE / NASDAQHealthcareLarge cap

$339.09-$2.16 (-0.6%)

Last close · Data as of Nov 20, 2026

Market cap
$52.6B
P/E
33.8x
EV / EBITDA
14.9x
Revenue
$321.3B
Net margin
0.5%
ROCE
21.0%

-6.3% over the last year

Cencora, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.2%
3M
+7.8%
6M
+28.1%
1Y
-6.3%
5Y
+181.4%

52-week range

Day change -$2.16 (-0.6%) from $341 to $339 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in COR, bought on each weekday since 2021.

News & filings

What Cencora filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernNet margin of 0.5% against a peer median of 13.1%.

Strengths (1)

  • Operating profit was 6.4 times interest costs.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

Read moreShow less

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Sector
Healthcare
Shares outstanding
193.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$52.6B
P/E
33.8x
P/B
34.9x
EV / EBITDA
14.9x
EV / Sales
0.2x
P/S
0.2x
52-week high
$374.75
52-week low
$252.74

Profitability

Operating margin
1.2%
Net margin
0.5%
EBITDA margin
1.2%
ROE
103.1%
ROCE
21.0%
ROA
2.0%
Asset turnover
4.20

Growth

Revenue
$321.3B
Revenue growth, 1Y
9.3%
Revenue CAGR, 3Y
10.4%
Net profit growth, 1Y
3.0%
Free cash flow
$3.2B

Solvency

Current ratio
0.90
Debt / Equity
5.08
Debt / Assets
0.10
CFO / Net profit
2.49
Cash / Market cap
8.3%

Where the revenue went

Of every $100 of FY2025 revenue, $0 was left as net income.

Cencora, Inc. income statement flow, FY2025
Cencora, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$309.9B
RevenueGross profit$11.5B
Gross profitSelling, general and administrative$6.5B
Gross profitOther operating expenses$1.1B
Gross profitOperating income$3.9B
Operating incomePretax income$2.3B
Operating incomeInterest and other expense$1.7B
Pretax incomeTax and other$704.2M
Pretax incomeNet income$1.6B

Revenue and net profit

Revenue grew 9.3% in FY2025; net profit is the dashed line.

Cencora, Inc. revenue and net profit by fiscal year
Cencora, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$238.6B$1.7B
FY2023$262.2B$1.7B
FY2024$294.0B$1.5B
FY2025$321.3B$1.6B

Cash flows

FY2025: $3.9B from operations, $3.2B free after investment (dashed).

Cencora, Inc. operating and free cash flow by fiscal year
Cencora, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$2.7B$2.2B
FY2023$3.9B$3.5B
FY2024$3.5B$3.0B
FY2025$3.9B$3.2B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$321.3B+9.3%1Y
EBITDA
$3.7B+11.1%1Y
Net profit
$1.6B+3.0%1Y
Cash from operations
$3.9B+11.2%1Y
Free cash flow
$3.2B+7.0%1Y
Revenue CAGR, 3Y
10.4%
Net profit CAGR, 3Y
-2.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$321.3B$3.7B$1.6B$3.2B103.1%+9.3%+3.0%

Monthly returns

Month-by-month returns of COR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$76.6B
Liabilities$74.8B
Equity$1.7B
Paid-in capital$6.2B
Retained earnings$6.5B
Treasury stock$10.3B
Minority interest$239.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; COR highlighted.

P/E against peers

COR trades at 33.8x earnings against a peer median of 32.8x.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Cencora, Inc.CORthis company$52.6B33.8x34.9x103.1%14.9x
Regeneron Pharmaceuticals, Inc.REGN$65.9B14.6x2.1x14.4%11.3x
Edwards Lifesciences CorporationEW$50.4B46.9x4.9x10.4%33.2x
Cardinal Health, Inc.CAH$47.2B30.3x-17.0x-56.1%16.7x
IDEXX Laboratories, Inc.IDXX$44.5B42.0x27.7x66.0%30.1x
Humana Inc.HUM$42.0B35.4x2.4x6.7%—
Becton, Dickinson and CompanyBDX$41.2B24.6x1.6x6.6%12.1x
Alnylam Pharmaceuticals, Inc.ALNY$40.5B129.2x51.4x39.8%61.6x
Agilent Technologies, Inc.A$39.1B30.0x5.8x19.3%22.1x
Peer median—32.8x3.6x12.4%22.1x

Year-to-date ROI

COR since 1 January, against earlier years.

Historical volatility

COR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Cencora, Inc. operating margin by fiscal year
Cencora, Inc. operating margin by fiscal year
DateOperating margin
FY20221.2%
FY20231.0%
FY20241.1%
FY20251.2%
LineFY2025
Cost of revenueCost Of Revenue$309.9B
Gross profitGross Profit$11.5B
Operating expensesOperating Expense$7.5B
Selling, general and administrativeSelling General And Administration$6.5B
Depreciation and amortisationDepreciation And Amortization In Income Statement$1.1B
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$1.1B
Depreciation income statementDepreciation Income Statement$494.1M
Amortization$556.9M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$556.9M
Total expensesTotal Expenses$317.4B
Pretax incomePretax Income$2.3B

Learn while you research

Academy chapters picked for Cencora, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 33.8, learn when high multiples are justified.6 min read
  3. 03 Leverage RatiosDebt/Equity of 5.08 is elevated, understand what that means for solvency.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →